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Abstract
Background: Paediatric chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME) is a relatively common
and disabling condition. The National Institute for Health and Clinical Excellence (NICE) recommends Cognitive
Behavioural Therapy (CBT) as a treatment option for paediatric CFS/ME because there is good evidence that it is
effective. Despite this, most young people in the UK are unable to access local specialist CBT for CFS/ME. A randomised
controlled trial (RCT) showed FITNET was effective in the Netherlands but we do not know if it is effective in the National
Health Service (NHS) or if it is cost-effective. This trial will investigate whether FITNET-NHS is clinically effective and
cost-effective in the NHS.
Methods: Seven hundred and thirty-four paediatric patients (aged 11–17 years) with CFS/ ME will be randomised (1:1)
to receive either FITNET-NHS (online CBT) or Activity Management (delivered via video call). The internal pilot study will
use integrated qualitative methods to examine the feasibility of recruitment and the acceptability of treatment. The full
trial will assess whether FITNET-NHS is clinically effective and cost-effective. The primary outcome is disability at 6 months,
measured using the SF-36-PFS (Physical Function Scale) questionnaire. Cost-effectiveness is measured via cost-utility
analysis from an NHS perspective. Secondary subgroup analysis will investigate the effectiveness of FITNET-NHS in those
with co-morbid mood disorders.
(Continued on next page)
* Correspondence: emma.anderson@bristol.ac.uk
1Centre for Child and Adolescent Health, Bristol Medical School: Population
Health Sciences, University of Bristol, Oakfield House, Oakfield, Grove, Bristol
BS8 2BN, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Baos et al. Trials  (2018) 19:136 
https://doi.org/10.1186/s13063-018-2500-3
(Continued from previous page)
Discussion: If FITNET-NHS is found to be feasible and acceptable (internal pilot) and effective and cost-effective (full trial),
its provision by the NHS has the potential to deliver substantial health gains for the large number of young people
suffering from CFS/ME but unable to access treatment because there is no local specialist service. This trial will provide
further evidence evaluating the delivery of online CBT to young people with chronic conditions.
Trial registration: ISRCTN registry, registration number: ISRCTN18020851. Registered on 4 August 2016.
Keywords: Paediatrics, Chronic fatigue syndrome, Myalgic encephalomyelitis, CFS/ME, CBT, E-health, Activity
management, Online systems, E-therapy, E-counselling
Background
Paediatric chronic fatigue syndrome/myalgic encephalitis
(CFS/ME) is common in the UK, with estimated preva-
lence between 1 and 2.4% [1, 2]. CFS/ME is defined as
disrupting and persistent generalised fatigue, diagnosed
after routine investigations have failed to identify an
alternative explanation for the fatigue [3, 4]. Young
people with CFS/ME are disabled [5, 6] and 30% of them
experience co-morbid anxiety and depression [7, 8].
They use significant healthcare resources [9] and put
substantial burden on their families [10].
The National Institute for Health and Clinical Excel-
lence (NICE) recommends that young people with CFS/
ME are offered either Cognitive Behavioural Therapy
(CBT, which focusses on strategies to identify, challenge
and change fatigue-related cognitive processes and grad-
ually resume activities), Graded Exercise Therapy (GET,
which stabilises physical activity levels, before gradually
increasing at a manageable rate) or Activity Manage-
ment (a goal-oriented and person-centred approach
which establishes a baseline for all activity, which is then
increased) [4, 11]. CBT and GET are moderately effective
in adults with CFS/ME [12–15]. There is good evidence
from randomised controlled trials (RCTs) that CBT is
effective for paediatric CFS/ME [16–19]. However, most
young people in the UK do not have access to a local
NHS specialist service offering CBT for CFS/ME. Some
children in the UK are able to access treatment (GET or
Activity Management) delivered as one face-to-face as-
sessment with Skype follow-up appointments.
The FITNET (Fatigue In Teenagers on the interNET)
trial carried out in the Netherlands [16] recruited 135 par-
ticipants between 2008 and 2010, and showed that
Internet-delivered CBT was effective compared to usual
care at 6 months. Young people were more likely to have
recovered; defined as no longer severely fatigued or phys-
ically impaired; attending school; and they perceived
themselves as completely/nearly completely recovered
(63% vs. 8%, relative risk 8.0, 95% CI 3.4–19.0; p < 0.0001).
None of the published paediatric trials reported on cost-
effectiveness and have either excluded young people with
co-morbid mood problems [17] or have not been powered
to investigate this group [16, 18, 19].
Methods
The aims of this trial are to investigate whether Internet-
delivered CBT, specifically designed for CFS/ME, (FIT-
NET-NHS) is effective and cost-effective compared to a
‘usual care’ comparator of Activity Management (delivered
via video call) for young people with CFS/ME who do not
have access to a local specialist paediatric CFS/ME service.
The trial is powered to explore effectiveness and cost-
effectiveness in young people with mild to moderate co-
morbid mood disorders.
This manuscript is in accordance with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines. See Additional file 1 for the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Checklist.
Trial design
This is an RCT comparing FITNET-NHS with Activity
Management for paediatric CFS/ME. An internal pilot
study will be conducted with continuation of the trial
based on achieving defined criteria. Integrated qualita-
tive methods will be used to optimise recruitment and
retention. Pilot data will be used in the effectiveness ana-
lyses unless changes to the interventions or trial design
are significant.
Setting and trial population
Young people will be assessed by their general practi-
tioner (GP), referred for local paediatric assessment and
investigated using NICE guidance [4]. If a diagnosis of
CFS/ME is made and there is no local specialist paediat-
ric CFS/ME service, GPs will be able to refer patients
diagnosed with CFS/ME to the Bath specialist paediatric
CFS/ME service. This is the standard referral pathway
for out-of-area patients.
Young people will be eligible if they are: (1) aged
11–17 years, (2) diagnosed with CFS/ME (using NICE
guidance [4]) and (3) do not have access to a local spe-
cialist paediatric CFS/ME service. Young people will be
excluded if any of the following apply: (1) they are not
disabled by fatigue (defined in eligibility screening), (2)
their fatigue is due to another cause, (3) they are unable
Baos et al. Trials  (2018) 19:136 Page 2 of 12
to complete video calls or FITNET-NHS online chapters
or (4) they report pregnancy at assessment.
Recruitment
The clinical team at the Bath specialist paediatric CFS/ME
service will identify potentially eligible young people re-
ferred to the service and telephone them and their
parents/carers to discuss treatment options, including the
option to take part in the trial. Young people and parents/
carers who are interested will be emailed an information
pack including: an age-appropriate Patient Information
Leaflet (PIL), and links to an online ‘consent to contact’
form and Revised Children’s Anxiety and Depression Scale
(RCADS) questionnaire [20, 21]. The ‘consent to contact’
form and RCADS questionnaire will be completed using a
secure electronic system used for data capture called Re-
search Electronic Data Capture http://project-redcap.org
(REDCap). After ‘consent to contact’ is completed an eligi-
bility assessment will be carried out with both the young
people and their parents/carers. Following this, the re-
cruitment consultation is performed. The eligibility assess-
ment and recruitment discussions usually take place
during one telephone/video call; however, they can also
take place over separate telephone/video calls if preferred.
These discussions will be audio-recorded with consent/
assent. The trial design and interventions will be ex-
plained; young people and their parents will be given the
opportunity to read the age-appropriate PIL, ask questions
and can have as long as required to make an informed de-
cision. The researcher will seek age-appropriate consent/
assent from the young person and parents/carers via the
online REDCap system. Those who decide not to take part
will be invited to talk to a qualitative researcher about
their decision and verbal agreement will be recorded dur-
ing the recruitment consultation. They will be offered a
face-to-face assessment and treatment by the Bath special-
ist paediatric CFS/ME service and continue to receive
standard medical care. Further consent for an interview
will be obtained at the time of the interview.
Randomisation
Participants will be randomised in a 1:1 ratio, by the re-
search team, to receive either FITNET-NHS or Activity
Management using an automated web randomisation
service. Allocation will use minimisation to facilitate
balance by age and gender, and preserve allocation con-
cealment. Because of the nature of the intervention, it is
not practical to blind either the participant, family or the
clinical service to treatment allocation. GPs will be in-
formed of the allocation.
Interventions
The Bath specialist paediatric CFS/ME service will pro-
vide both treatment arms. Both interventions will be
delivered so that participants receive treatment at home,
online. The Activity Management arm is akin to usual
care for out-of-area referrals, who would normally have
an assessment (face-to-face) with follow-ups via video
call. The difference with Activity Management delivered
within the FITNET-NHS Trial is that participants do
not need to travel for the initial assessment as this too is
delivered via video call. See Fig. 1 for the standard refer-
ral and treatment pathway for out-of-area patients,
compared with the trial processes.
Activity Management (comparator)
Activity Management via video call will be delivered by
specialist therapists (occupational therapists, physiother-
apists, psychologists, physicians and nurses). Participants
will have three to six video appointments (one assess-
ment and up to five follow-ups). Parent/carer attendance
is optional.
During the assessment (around 90 min), the therapists:
will discuss the different types of activity – including
cognitive activity (high concentration and low concen-
tration) – which vary according to age; carry out a
detailed assessment of the individual’s current activity
levels; and collaboratively agree a ‘baseline’, which is the
average level of activity. Participants will receive infor-
mation on CFS/ME, activity management, sleep and
symptom management.
The first follow-up video call will be arranged 2 to 6
weeks after assessment depending on participant prefer-
ence. If the patient still requires clinical care further
follow-up video calls will be organised from 2 to 6 weeks
later. During the follow-up video calls (around 60 min
each) the therapist will review activity and sleep and
help participants to problem-solve. Participants will be
encouraged to increase activity between sessions.
Therapists will complete a checklist to indicate which
mandatory, flexible and prohibited items were discussed
at each session. These items are listed in Table 1.
Following the video calls the therapists will hand care
over to the local nominated clinician in primary/secondary
care. Therapists will discuss the case with the nominated
clinician by telephone/letter (as normal clinical practice),
ask for a review within 6–8 weeks and offer up to three
telephone calls to advise on treatment options, overcom-
ing barriers and symptom control. Local providers mostly
offer face-to-face follow-up, some may use telephone.
FITNET-NHS (intervention)
FITNET is an Internet-delivered CBT package created for
paediatric CFS/ME in the Netherlands [16, 17]. The
programme has 19 psycho-educational and CBT chapters
for young people and a parallel programme for their par-
ents. Participants and their parents have separate accounts
and log-ins. The psycho-educational chapters include
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information on: CFS/ME; the causes of CFS/ME; the rela-
tionship between CFS/ME, anxiety, depression and other
illnesses; how diagnosis is confirmed; treatment for CFS/
ME; how to explain CFS/ME to friends and what the
future (without CFS/ME) is likely to look like.
The CBT section is activated by a clinical psychologist
once the young person/parent has completed the
psycho-educational chapters. Parental chapters explore
and address parents’ beliefs and behaviours towards their
child with CFS/ME, focussing on their role as carers. In
participants younger than 15 years, parents/carers are
supported to act as a coach. In those older than 15 years,
parents/carers are encouraged to step back and support
their child taking responsibility for their treatment. The
CBT chapters focus on cognitive behavioural strategies
with instructions on exercises for identifying, challenging
and changing cognitive processes that contribute to
CFS/ME and increasing self-efficacy with respect to fa-
tigue, the ability to be active and work towards recovery.
There are two protocols depending on the pattern of
activity levels. If participants are identified as being rela-
tively active with a varying level of activity, they first find
their baseline before increasing slowly. If they are de-
fined as being ‘low active’ with little variation in activity,
they immediately start with increasing activity [17].
Chapters 1 to 4 introduce CBT and explain the role of
therapists, present CFS/ME as a multifactorial model
with predisposing, precipitating and maintaining factors
and discuss the role of the family. Chapter 4 focus on
treatment goals including the goal of full-time education
and chapter 5 focusses on regulation of sleep-wake
patterns. Chapters 6 to 19 focus on cognitive behavioural
strategies with instructions on exercises on identifying,
challenging and changing cognitive processes that con-
tribute to CFS/ME. While participants are able to
complete the chapters at their own pace, they are en-
couraged to work on, and complete, chapters before the
next e-consultation.
Fig. 1 The trial treatment pathway identifies differences between the standard care (multidisciplinary treatment provided by the clinical care
team as per NICE guidance) and research trial treatment pathways
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The FITNET-NHS clinical psychologists will provide
e-consultations (email exchange between therapist and
participant on the FITNET platform) approximately
every 1 to 2 weeks with timings negotiated between
therapist and participant. In addition, participants and
parents are required to complete homework/tasks (for
example, sleep-wake, and thoughts and feelings diaries).
These will be discussed in the e-consultations and used
to support behaviour change. The therapist will work
with parents and young people separately.
All FITNET-NHS clinical psychologists receive train-
ing in how to deliver CBT for CFS/ME and receive regu-
lar supervision from experienced CBT therapists.
Duration of treatment period
Those allocated to FITNET-NHS will receive treatment
for approximately 6 months but this will vary depending
on how long it takes participants and their parents to
complete the online chapters.
Participants allocated to Activity Management will re-
ceive treatment for 3 to 6 months. It will vary depending
on the number of sessions (three to six) in the treatment
course and the gap between follow-up sessions.
After completion of the treatment, patients will be dis-
charged from the Bath specialist paediatric CFS/ME
service to their local GP.
Treatment adherence
For both trial arms we will use therapist-assessed
treatment adherence with three possible ratings: (1)
non-starter (no sessions attended), (2) started then
stopped sessions, (3) majority (approximately 80% +)
completer (all or majority of sessions attended in line
with what is clinically relevant). New chapters within the
FITNET-NHS programme are only unlocked by the
therapist on completion of specific tasks/homework, and
some chapters are opened only if clinically relevant. We
will assume that participants and parents completing
treatment find the interventions acceptable. Acceptabil-
ity will also be assessed through qualitative interviews.
Participants can withdraw from the trial at any time
without giving a reason. The participant flow diagram is
shown in Fig. 1.
Outcome measures
The following data will be collected from participants at
the clinical assessment: age, sex, post code, ethnicity,
symptoms (Centers for Disease Control and Prevention
(CDC) and NICE criteria), months of illness, and diag-
noses of co-morbid illnesses. At baseline participants
will complete the following questionnaires: SF-36 phys-
ical function subscale (SF-36-PFS) [22], fatigue (using
the Chalder Fatigue Scale and the Checklist Individual
Strength (CIS) [23] fatigue severity subscale), school at-
tendance, RCADS [21, 24], pain Visual Analogue Scale
[25], EQ-5D-Y (EuroQoL health-related quality of life
questionnaire, Youth version) [26] and the Clinical Glo-
bal Impression Scale questionnaire [27], the Cognitive
Behavioural Responses to Symptoms Questionnaire
(CBRSQ) [28, 29] and the Children’s Negative Cognitive
Error Questionnaire Revised (CNCEQ-R) [30]. Parents
will complete the following questionnaires at baseline:
an adapted existing Healthcare Resource Use question-
naire to measure health service use and the adapted six-
item Work Productivity and Activity Impairment Ques-
tionnaire General Health V2.0 (WPAI:GH) [31].
The primary outcome is disability measured using the
SF-36-PFS 6 months after randomisation.
Secondary outcomes will be measured at 3-, 6- and
12-month follow-ups unless otherwise stated: SF-36-PFS
measured at 3 and 12 months after randomisation; fa-
tigue (Chalder Fatigue Scale and CIS); school attendance;
RCADS); pain Visual Analogue Scale; Clinical Global
Impression Scale; EQ-5D-Y; parental completed: Health-
care Resource Use questionnaire; WPAI:GH. All these
measures are important and relevant domains [32] that
are used in UK services, Child and Adolescent Mental
Table 1 Outline of mandatory, flexible and prohibited elements
from the Activity Management protocol
Mandatory Discussing different types of activity (cognitive and physical)
which vary according to age
Finding a baseline level of activity (physical activities vary
according to severity)
Discussing different types of high-energy cognitive activities
which require concentration, e.g. time at school, school
work, reading, some crafts/hobbies, socialising and screen
time (phone, TV, computer, other devices)
Discussing physical activities, which vary according to
severity (e.g. severely affected – sitting up in bed; mildly
affected – running)
Using paper/electronic diaries (including iPhone/iPad app
‘ActiveME’) to record time spent each day doing high-energy
cognitive activities
Increasing activity by 10–20% each week [4, 16]
Problem solving
Managing setbacks
Flexible Advice on exercise
Discussing a diagnosis and treatment of anxiety and/or
depression
Advice on medication (if required)
Advice on symptom control (if required)
Prohibited Detailed discussion of feelings, beliefs and how they change
Diaries on feelings and their relationship with behaviour
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Health Services (CAMHS) and/or tested in previous trials
[16, 33, 34].
All data will be collected on REDCap and anon-
ymised at source. Table-based authentication will be
used which utilises the storage of username/password
pairs in a database table. Participants will be sent a
web link to REDCap which will only allow access to
their data. All data will either be stored on secure
University of Bristol servers and or in secure locked
cabinets. They will create a password which they will
use each time they log in. The schedule of data col-
lection is shown in Fig. 2, the SPIRIT Figure [35]. An
email will be sent to participants with a link to
complete questionnaires online. If these are not com-
pleted, two automated reminders will be sent and
then we will telephone participants where possible. If
this is not successful, an email with a link to a
reduced set of questionnaires will be sent out (SF-36-
PFS, Chalder Fatigue Scale, school attendance,
EQ-5D-Y and Clinical Global Impression Scale).
Sample size
Full trial: we plan to randomise 734 young people in the
full trial. The study will proceed to full trial assuming the
stop criteria (see below) are not met. Assuming 10% attri-
tion (withdrawal or non-provision of primary outcome
data) [16, 33], data on 660 young people will be available
for the primary analysis. This gives 97% power at 1%
significance to detect a 0.35-SD difference in treatment ef-
fect on the SF-36-PFS. The analysis of effectiveness in 198
young people with co-morbid mood disorders of anxiety
and depression (30% of those recruited and with data
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: schedule of enrolment, interventions and data collection [35]
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available for analysis (after 10% attrition)) will have 80%
power to detect a 0.4-SD difference at 5% significance. A
difference of 10 points on the SF-36-PFS is considered to
be the Minimal Clinically Important Difference (MCID)
[36, 37]. The mean SF-36-PFS is 49.8 with SD 24.8 in
young people with CFS/ME at assessment by the Bath
specialist paediatric CFS/ME service (n = 1075). A 0.4-SD
is 9.92 and, therefore, our trial is powered to detect the
MCID of 10 in young people with co-morbid mood disor-
ders of anxiety and depression.
We will perform sensitivity analyses on young people
who fulfil the CDC diagnostic criteria. We estimate this
will be 80% of those randomised (529 after 10% attrition)
which will give us 98% power to detect a difference in
treatment effect of 0.35 SD at 5% significance, which is
at least the MCID.
Outcomes and analyses of the internal pilot study
The internal pilot study will run for 12 months using
integrated qualitative methods to determine feasibility
of trial processes and acceptability of interventions.
Defined criteria (see below) will be used to determine
whether the study should proceed to full trial, in which
case data from the internal pilot phase will be included
in full trial analysis.
Feasibility of recruitment
We will present as a Consolidated Standards of Reporting
Trial (CONSORT) flow chart the number (%) of those
referred who: were contacted by the research team, were
screened for eligibility, received recruitment consultation
and consented. The number of referrals and the number
recruited between different regions of the UK will be com-
pared. Retention at 6 months will be calculated, defined as
the proportion of participants providing outcome data
between 5 and 9 months after randomisation.
Audio-recordings of eligibility and recruitment discus-
sions will be analysed regularly, focussing on the inter-
action between recruiter and potential participant in
terms of information provision, recruitment techniques,
intervention preferences and trial participation decisions.
This will be assessed in combination with data from
in-depth interviews conducted with young people and
their families soon after their consultation to explore
provision and acceptability of patient information, rea-
sons for accepting or declining participation, reasons for
declining treatment allocation and dropouts, prior
exposure to treatments, and beliefs, expectations and
preferences about treatments. Screening logs will be
scrutinised frequently to identify any recruitment issues,
and interviews with members of the clinical and recruit-
ing team will be undertaken to explore issues around
trial feasibility if difficulties arise.
Acceptability of FITNET-NHS and Activity Management
Young people and their families who agreed to participate
in the trial will be invited to an interview to assess their
experience and acceptability of the trial interventions after
having had exposure to them. Information will also be col-
lected from interviews with trial staff on the feasibility and
acceptability of delivering the interventions.
Sampling for interviews will ensure that a range of
informants in terms of age, gender, ethnicity, geograph-
ical location, and severity of condition are included
(maximum variation sampling), with further sampling
being guided by emerging findings (theoretical sam-
pling). Sample size will be determined by data satur-
ation, i.e. where no new themes emerge. Topic guides
developed from the academic literature and clinical ex-
perience will be used to ensure interviews cover the
same issues while allowing new issues of importance to
emerge. All interviews will be audio-recorded with con-
sent using encryption software, transcribed verbatim and
anonymised. Interviews will mostly take place via
telephone or video call, or face-to-face where feasible.
Analysis of qualitative data will be an ongoing and
iterative process commencing soon after data collection
to inform further sampling and data collection. Tran-
scripts will be imported into NVivo, systematically
assigned codes and analysed thematically using tech-
niques of constant comparison [38]. Individuals exhibit-
ing contrasting attitudes (‘negative cases’) will be studied
in detail. The perspectives of the individuals will be
paramount, with careful account taken of the context
within which the discussion takes place. To check cod-
ing reliability, a proportion of transcripts will be double
coded and findings compared.
A purposeful selection of audio-recordings of eligibility
and recruitment sessions will be analysed using content
analytic methods [39] to describe in a structured manner
what was said by whom and how often. More flexible
Grounded Theory methods will be applied to identify
common or divergent themes, particularly focussing on
the impact of statements by the recruiter on patients.
Targeted analyses focussing on certain sections of re-
cruitment transcripts; for example, the interactions dur-
ing which randomisation is offered, will be carried out
to enable areas of difficulty to be explored in depth [40].
Sources of difficulties identified through the integrated
qualitative research will be discussed with the trial man-
agement group and suggestions made to change aspects
of the design, conduct, organisation or training of re-
cruiters that could then lead to improvements in how
the internal pilot study/full RCT is conducted.
Stop criteria
The stop criteria have been agreed with the Trial Steer-
ing Committee (TSC) prior to starting recruitment. The
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internal pilot study will not proceed to full trial if: (1)
the recruitment rate is substantially below target during
the last 6 months of the internal pilot study and if the
qualitative data suggests that we cannot improve recruit-
ment by changing recruitment methods or (2) the quali-
tative data suggests that the interventions are not
acceptable to participants.
Outcomes and analyses of the full trial
Effectiveness of FITNET-NHS compared to Activity
Management
The primary outcome will be disability at 6 months
measured by the SF-36-PFS.
We will compare the mean SF-36-PFS scores at 6
months according to randomised allocation among partic-
ipants with measured outcomes, using multivariable linear
regression adjusting for baseline values of the outcome,
baseline age and gender. Similar regression analyses will
be conducted for secondary outcomes (linear regression
for numerical outcomes and logistic regression for binary
outcomes). For the primary outcome, we will conduct sen-
sitivity analyses in which we also adjust for any prognostic
variables for which there is a baseline imbalance between
intervention arms. Further sensitivity analyses will use
imputation for missing data (if appropriate). Three-month
and 12-month outcome data will be analysed similarly.
We will present summary statistics for the SF-36-PFS (at
baseline, 3 months, 6 months and 12 months) for the par-
ticipants allocated to FITNET-NHS who did and who did
not complete at least module 19, as an initial investigation
of the benefit of the intervention among those participants
who were able to engage fully with it. We will conduct
sensitivity analyses estimating the effectiveness of
FITNET-NHS compared with Activity Management for
the primary outcome only restricted to participants who
fulfilled the CDC diagnostic criteria for CMS/ME at the
time of recruitment to the trial.
Analyses of effectiveness for those with co-morbid mood
disorders
We will estimate the effectiveness of FITNET-NHS com-
pared with Activity Management on the primary outcome
in participant subgroups defined by the presence or ab-
sence of baseline anxiety or depression, by using the age-
and gender-specific clinical thresholds for each subscale
on the RCADS. Evidence that the intervention effect
differs between subgroups will be examined by adding
interaction terms to the multivariable linear regression
model for the primary outcome only.
Cost-effectiveness of FITNET-NHS and Activity Management
Our primary economic evaluation will compare differ-
ences in NHS costs and health outcomes, measured in
Quality-adjusted Life Years (QALYs), between participants
randomised to FITNET NHS and Activity Management in
a cost-utility analysis.
NHS costs will include the costs of delivering each
intervention (including future licence fee costs). We will
record the number of video consultations in the Activity
Management arm and the number of e-consultations in
the FITNET-NHS arm. At each follow-up time point (3,
6 and 12 months) parents will be asked to complete an
adapted resource-use questionnaire to measure the
young person’s health service use (e.g. GP, specialist care
or medications) as well as educational service (e.g.
school counsellor) and family expenses in the last 3
months. We will also quantify the impact of the young
person’s health on parental work using the WPAI:GH. In
addition, Hospital Episode Statistics (HES) data and the
Mental Health and Learning Disabilities Data Set
(MHLDDS) from the Health and Social Care Informa-
tion Centre (HSCIC) will be used to measure paediatric
and CAMHS use in both arms. Resource use will be val-
ued using national unit costs where available.
We intend to use the EQ-5D-Y to calculate QALYs. A
valuation tariff for the EQ-5D-Y is being developed but
is not yet available [41]. Some researchers have used the
adult valuation tariff to estimate an index score for the
EQ-5D-Y, although this may misrepresent young people’s
values [42]. At the time of analysis, we will use the
EQ-5D-Y valuation tariff, if available.
Depending on the prevalence of missing cost and out-
come data, we may use simple or multiple imputation
methods in our primary analysis. We will use a threshold
willingness-to-pay of £20,000 per QALY [43] to estimate
the incremental net monetary benefits of FITNET-NHS.
We will use non-parametric bootstrapping methods to
calculate 95% confidence intervals and create a cost-
effectiveness acceptability curve to estimate the prob-
ability that FITNET-NHS is cost-effective at varying
willingness-to-pay thresholds. Between-group analyses of
incremental costs, QALYs and net benefits will be ad-
justed for age, gender and baseline EQ-5D-Y score.
Analyses of cost-effectiveness for those with co-morbid
mood disorders
In a secondary economic analysis, we will estimate cost-
effectiveness acceptability curves for improvement in the
primary outcome measure (SF-36-PFS). We will use net
benefit regression to assess whether there is an inter-
action between cost-effectiveness and the presence of
anxiety or depression at baseline. We will quantify non-
NHS costs and compare them between trial arms to
judge whether they strengthen or weaken the interpret-
ation of the primary economic evaluation.
Missing data from parental healthcare resource-use
questionnaires from general practice records will be col-
lected through data linkage, and will be used to check
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accuracy of reported healthcare resource use and to de-
termine how many young people develop other illnesses.
Safety
We will prospectively collect data on serious and non-
serious adverse events reported to the clinician or re-
search team during the intervention and follow-up
period. These will be reported according to the sponsor’s
guidelines. We will investigate whether young people
randomised to one arm are at higher risk of having a
serious deterioration in health compared to another
arm. We will define a serious deterioration in health as:
(1) clinician-reported serious deterioration in health, (2)
a decrease of ≥ 20 in SF-36-PFS between baseline and 3,
6 or 12 months or scores of ‘much’ or ‘very much’ worse
on the Clinical Global Impression Scale or (3) with-
drawal from treatment because of feeling worse.
Safety outcomes will be analysed by the Data and
Safety Monitoring Committee (DSMC) at 11 months
after the start of recruitment, before the trial progresses
from internal pilot to full trial and when approximately
50% of participants have been recruited (estimated 23
months after the start of recruitment).
Following the baseline mood assessment (using
RCADS), the research team will not routinely monitor de-
pression or anxiety. Participants will be made aware of this
and if they are worried about anxiety or depression, or dis-
close information about this during the course of the trial,
they will be advised to discuss this with their routine care
providers (e.g. GP, paediatrician), and clinicians will
inform them about relevant services if appropriate. Partic-
ipants will be made aware that if they report any serious
problem outside of business hours, it may not be
followed-up until business hours resume and they should
contact their GP, paediatrician or emergency service.
Discussion
Young people with CFS/ME should be offered referral to a
specialist paediatric CFS/ME service [4]. However, most
young people in the UK do not have access, or must travel
very long distances to an NHS specialist service offering
NICE-recommended treatments including Activity Man-
agement or CBT for CFS/ME. There is an evidence base
for the using CBT to treat paediatric CFS/ME. However,
none of the published paediatric trials have reported on
cost-effectiveness. Although Internet-delivered CBT ap-
pears to be potentially useful, further evaluation is
required before it is used within the NHS [44].
Strengths and limitations
This will be the largest RCT conducted in paediatric CFS/
ME. It is designed to investigate the effectiveness and
cost-effectiveness of using FITNET-NHS, delivering on-
line CBT, compared to Activity Management delivered via
video calls, to treat paediatric CFS/ME in the UK. If effect-
iveness and cost-effectiveness are demonstrated for either
arm, the NHS has the potential to deliver substantial
health gains for the large number of young people suffer-
ing from CFS/ME but unable to access treatment because
there is no local specialist service. If it is feasible this
method could be used for other long-term conditions
where young people do not have local specialist services.
Results from the qualitative methods will tell us about
patient experiences of the intervention content and mode
of delivery, how to improve these types of interventions
and how to deliver treatment from a single centre in the
UK. Results will be disseminated as widely as possible
including: open-access journals, conferences and public
events. This is likely to benefit young people from other
conditions, their families, clinicians and the NHS.
There is currently limited evidence of treatment effect
in children with co-morbid mood disorders [45]. Most,
but not all [46], studies in adults suggest that CBT is less
effective in patients with co-morbid depression [47–49].
Anxiety and depression is common for young people with
CFS/ME [8, 50, 51]. FITNET-NHS is designed to treat
young people with co-morbid mood disorders as well as
CFS/ME and this trial is powered to test whether the effects
of FITNET-NHS differ in this subgroup of young people.
Our trial design includes usual care delivered by a spe-
cialist service. This is because it was felt to be unethical to
offer no treatment to children in the control arm, though
for many children in the UK ‘usual care’ is no treatment.
As Activity Management and CBT are behavioural inter-
ventions it is not feasible to blind participants or clinicians
to allocation. However, the research team have worked to
ensure the information sheets present the two treatments
in a balanced way, and recruiters have had training to try
and encourage participant equipoise. The analyses will be
conducted by a researcher blinded to treatment allocation.
As we are investigating CFS/ME, the outcomes are
patient-reported outcomes. These outcomes are consist-
ent with illness domains that are the most important to
patients. The outcomes at follow-up are not reported to
clinicians to reduce performance bias.
There is potential for contamination between interven-
tions because of contact between therapists of two treat-
ment arms (working in the same treatment centre);
however, both treatment arms are protocolised and adher-
ence will be checked.
If differences in effectiveness are found between the
treatments, further research will be required to explore
mechanisms of effectiveness.
Trial status
Opened to recruitment November 2016. Recruitment is
ongoing into 2020. For details see: www.bristol.ac.uk/fit
net-nhs/.
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